Login to Your Account

Stallergenes, Greer in $120M U.S. Pact on Grass Allergy Drug

By Cormac Sheridan
Staff Writer

Friday, November 1, 2013
Stallergenes SA could receive up to $120 million in regulatory and sales-based milestones from a U.S. commercialization agreement with Greer Laboratories Inc., involving its investigational grass allergy treatment Oralair. Antony, France-based Stallergenes will be responsible for the production of the Oralair sublingual tablets, for which it will receive an undisclosed transfer price. It also stands to receive sales royalties on the product.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription